WHO Expert Committee on Selection and Use of Essential Medicines - WHO Technical Report Series, No. 850, Annex 3 (Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products) - Sixth Report
(1995; 36 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentINTRODUCTION
View the documentGLOSSARY
Open this folder and view contents1. PROVISIONS AND PREREQUISITES FOR A CLINICAL TRIAL
View the document2. THE PROTOCOL
Open this folder and view contents3. PROTECTION OF TRIAL SUBJECTS
Open this folder and view contents4. RESPONSIBILITIES OF THE INVESTIGATOR
Open this folder and view contents5. RESPONSIBILITIES OF THE SPONSOR
Close this folder6. RESPONSIBILITIES OF THE MONITOR
View the document6.1 Qualifications
View the document6.2 Assessment of the trial site
View the document6.3 Staff education and compliance
View the document6.4 Data management
View the document6.5 Case-report forms
View the document6.6 Investigational product
View the document6.7 Communication
View the document6.8 Notification of the trial or submission to the drug regulatory authority
View the document6.9 Reports
Open this folder and view contents7. MONITORING OF SAFETY
Open this folder and view contents8. RECORD KEEPING AND HANDLING OF DATA
Open this folder and view contents9. STATISTICS AND CALCULATIONS
Open this folder and view contents10. HANDLING OF AND ACCOUNTABILITY FOR PHARMACEUTICAL PRODUCTS
Open this folder and view contents11. ROLE OF THE DRUG REGULATORY AUTHORITY
View the document12. QUALITY ASSURANCE FOR THE CONDUCT OF A CLINICAL TRIAL
View the document13. CONSIDERATIONS FOR MULTICENTRE TRIALS
View the documentREFERENCES
View the documentAPPENDIX 1: World Medical Association’s Declaration of Helsinki1
View the documentAPPENDIX 2: Model list of items to be contained in a clinical trial protocol
 

6.5 Case-report forms

The monitor is responsible for ensuring that all case-report forms (CRFs) are correctly filled out in accordance with original observations. Any errors or omissions should be clarified with the investigator, corrected, and explained on the CRF. Procedures should be established for the investigator’s certification of the accuracy of CRFs by a signature, initials or similar method. All procedures for ensuring accuracy of CRFs must be maintained throughout the course of the clinical trial.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014